Kiora Pharmaceuticals (KPRX) Common Equity (2014 - 2026)
Kiora Pharmaceuticals' (KPRX) quarterly Common Equity came in at $13.9 million in Q1 2026, down 41.21% YoY from $23.7 million in Q1 2025, and down 13.59% on a QoQ basis from $16.1 million in Q4 2025.
Kiora Pharmaceuticals (KPRX) Common Equity (2014 - 2026) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 13 years of Common Equity data on file, last reported at $13.9 million in Q1 2026.
- Quarterly Common Equity fell 41.21% year-over-year to $13.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.9 million (down 41.21% YoY) and the FY2025 annual result came in at $16.1 million, down 37.4% from the prior year.
- Common Equity declined to $13.9 million in Q1 2026, from $16.1 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $34.9 million in Q1 2024 to a low of $6.1 million in Q4 2023.
- A 5-year average of $17.8 million and a median of $13.9 million in 2026 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity surged 601.42% — and 2023, when it plunged 46.44%.
- Tracing KPRX's Common Equity over 5 years: stood at $11.4 million in 2022, then sank by 46.44% to $6.1 million in 2023, then surged by 321.62% to $25.8 million in 2024, then sank by 37.4% to $16.1 million in 2025, then fell by 13.59% to $13.9 million in 2026.
- The last three Common Equity figures came in at $13.9 million (Q1 2026), $16.1 million (Q4 2025), and $22.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.49 Bn | 54.36 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.02 Bn | 36.92 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.79 Bn | 27.48 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.26 Bn | 9.87 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.30 Bn | 26.14 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.10 Bn | 26.26 Bn | - | 9.79 Bn |
| 10 | Kiora Pharmaceuticals | 16.06 Mn | 16.06 Mn | - | 16.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.86 Mn |
| Mar 31, 2026 | 13.93 Mn |
| Dec 31, 2025 | 16.13 Mn |
| Sep 30, 2025 | 22.41 Mn |
| Jun 30, 2025 | 22.13 Mn |
| Mar 31, 2025 | 23.70 Mn |
| Dec 31, 2024 | 25.76 Mn |
| Sep 30, 2024 | 30.03 Mn |
| Jun 30, 2024 | 33.10 Mn |
| Mar 31, 2024 | 34.90 Mn |
| Dec 31, 2023 | 6.11 Mn |
| Sep 30, 2023 | 8.10 Mn |
| Jun 30, 2023 | 13.64 Mn |
| Mar 31, 2023 | 10.16 Mn |
| Dec 31, 2022 | 11.41 Mn |
| Sep 30, 2022 | 10.52 Mn |
| Jun 30, 2022 | 8.76 Mn |
| Mar 31, 2022 | 11.26 Mn |
| Dec 31, 2021 | 14.58 Mn |
| Sep 30, 2021 | 1.50 Mn |